C
Charles C. Wykoff
Researcher at Houston Methodist Hospital
Publications - 268
Citations - 15240
Charles C. Wykoff is an academic researcher from Houston Methodist Hospital. The author has contributed to research in topics: Medicine & Visual acuity. The author has an hindex of 41, co-authored 200 publications receiving 12730 citations. Previous affiliations of Charles C. Wykoff include Cornell University & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Patrick H. Maxwell,Michael S. Wiesener,Gin-Wen Chang,Steven C. Clifford,Emma C. Vaux,Matthew Edward Cockman,Charles C. Wykoff,Christopher W. Pugh,Eamonn R. Maher,Peter J. Ratcliffe,Peter J. Ratcliffe +10 more
TL;DR: It is indicated that the interaction between HIF-1 and pVHL is iron dependent, and that it is necessary for the oxygen-dependent degradation of HIF α-subunits, which may underlie the angiogenic phenotype of VHL-associated tumours.
Journal Article
Hypoxia-inducible Expression of Tumor-associated Carbonic Anhydrases
Charles C. Wykoff,Nigel J. P. Beasley,Peter H. Watson,Kevin Turner,Jaromir Pastorek,Amen Sibtain,George S. Wilson,Helen Turley,Kate L. Talks,Patrick H. Maxwell,Christopher W. Pugh,Peter J. Ratcliffe,Adrian L. Harris +12 more
TL;DR: A new class of HIF-1-responsive gene is defined, the activation of which has implications for the understanding of hypoxic tumor metabolism and which may provide endogenous markers for tumor hypoxia.
Journal ArticleDOI
Diabetic Retinopathy: A Position Statement by the American Diabetes Association.
Sharon D. Solomon,Emily Y. Chew,Elia J. Duh,Lucia Sobrin,Jennifer K. Sun,Brian L VanderBeek,Charles C. Wykoff,Thomas W. Gardner +7 more
TL;DR: Improvements in medications and devices for the systemic therapy of diabetes have also improved the ability of patients to optimize their metabolic control, and this Position Statement incorporates these recent developments for the use of physicians and patients.
Journal ArticleDOI
HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron
Stefano J. Mandriota,Kevin Turner,David R. Davies,Paul Murray,Neil V. Morgan,Heidi M. Sowter,Charles C. Wykoff,Eamonn R. Maher,Adrian L. Harris,Peter J. Ratcliffe,Patrick H. Maxwell +10 more
TL;DR: It is shown that in the kidneys of patients with VHL disease, HIF activation is an early event occurring in morphologically normal single cells within the renal tubules, while dysplastic lesions, cystic lesions, and tumors showed evidence of additional mechanisms that amplify HIFactivation.
Journal ArticleDOI
Prognostic Significance of a Novel Hypoxia-Regulated Marker, Carbonic Anhydrase IX, in Invasive Breast Carcinoma
Stephen Chia,Charles C. Wykoff,Peter H. Watson,Cheng Han,Russell Leek,Jaromir Pastorek,Kevin C. Gatter,Peter J. Ratcliffe,Adrian L. Harris +8 more
TL;DR: CA IX expression was associated with worse relapse-free survival and overall survival in an unselected cohort of patients with invasive breast carcinoma, and the potential role of CA IX as a marker of hypoxia within breast carcinomas was also indicated by a significant association with necrosis.